“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
Neurourology and Urodynamics · 2026
DOI: 10.1002/nau.70216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2026. Verfasst von Vada Furlan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of California Irvine, Orange, California, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Neurogenic, Urinary Bladder, Neuromuscular Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIH/NIDDK.
Abstract (Originalsprache)
Objectives
Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative. Materials and Methods A PubMed search identified 81 studies on NLUTD and BoNT‐A, 26 of which were analyzed for the efficacy of BoNT‐A as a first‐line treatment.
Results
BoNT‐A significantly improved renal function and urinary continence, as indicated by significant reductions in maximum detrusor pressure and increases in maximum cystometric capacity, respectively. Mechanisms for which BoNT‐A treatment also improved urinary urgency were found to include sensory pathway modulation and neurotransmitter inhibition. Finally, QoL was found to significantly improve across multiple criteria, including sexual function such as lubrication and orgasm. Importantly, early initiation of BoNT‐A treatment yielded better outcomes, emphasizing its value as a first‐line treatment. Although side effects include increased post‐void residual (PVR), pain, muscle weakness, and reduced efficacy over time, studies have shown that these effects are manageable with dose adjustments and anesthetics.
Conclusion
BoNT‐A offers substantial therapeutic benefits for NLUTD and demonstrates greater effectiveness when used early; thus, it should be considered a first‐line treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of California Irvine, Orange, California, USA.
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
- NIH/NIDDK
Zitieren
APA
Furlan, V., Kobayashi, A., & Sadeghi, Z. (2026). “What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70216
Vancouver
Furlan V, Kobayashi A, Sadeghi Z. “What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70216
BibTeX
@article{Furlan2026,
author = {Furlan, Vada and Kobayashi, Alyssa and Sadeghi, Zhina},
title = {“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox},
journal = {Neurourology and Urodynamics},
year = {2026},
doi = {10.1002/nau.70216}
}
EUVIMED